Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Crispr Therapeutics Ag
(NQ:
CRSP
)
48.69
+1.19 (+2.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Crispr Therapeutics Ag
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
28
29
Next >
Is Editas Medicine Stock a Buy Now?
February 03, 2023
Layoffs and a thin clinical-stage pipeline aren't very encouraging.
Via
The Motley Fool
3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later
February 02, 2023
CRISPR stocks are heating back up after a difficult 2022. These three names should be at the top of your watchlist.
Via
InvestorPlace
Michael Burry vs. Jim Cramer: Is It Time to Buy or Sell Stocks Now?
February 02, 2023
Michael Burry thinks investors should sell stocks right now. Jim Cramer thinks they should buy more. Which expert is right in this case?
Via
InvestorPlace
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
February 01, 2023
Via
Benzinga
Jim Cramer Says This Is 'One Of Those Crazy Science Stocks That In This Market Will Work Perfectly'
February 01, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he really likes Qualtrics International Inc (NASDAQ: XM) as a
Via
Benzinga
3 Things About CRISPR Therapeutics That Smart Investors Know
January 31, 2023
The gene-therapy specialist's near-term outlook is quite bullish.
Via
The Motley Fool
5 Reasons to Buy Vertex Pharmaceuticals Now
January 18, 2023
Vertex shares are extending last year's gains, and that trend probably isn't over.
Via
The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
January 14, 2023
Vertex is heading for a new phase of growth.
Via
The Motley Fool
Expert Ratings for CRISPR Therapeutics
January 05, 2023
Via
Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.
Via
InvestorPlace
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
January 27, 2023
These companies have the therapies to boost revenue for a decade.
Via
The Motley Fool
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later
January 25, 2023
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.
Via
InvestorPlace
3 Gene Editing Stocks With the Best Long-Term Potential
January 25, 2023
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space
Via
InvestorPlace
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
January 22, 2023
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.
Via
The Motley Fool
3 Smart Stocks to Buy if a Recession Is on the Way
January 21, 2023
Their products will enjoy strong demand regardless of what happens with the economy.
Via
The Motley Fool
CRISPR Therapeutics Stock: Bull vs. Bear
January 19, 2023
Should investors buy this risky biotech stock as the company moves toward bringing its first major treatment to market?
Via
The Motley Fool
7 Biotech Stocks That Will Make You Rich in 10 Years
January 18, 2023
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.
Via
InvestorPlace
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
January 18, 2023
CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in 10 years.
Via
InvestorPlace
2 Stocks Down More Than 25% to Buy Right Now
January 16, 2023
These companies are set for a new era of growth.
Via
The Motley Fool
5 Potentially Explosive Stocks to Buy in 2023
January 13, 2023
These stocks all dropped in the double digits last year. But their future prospects are brilliant.
Via
The Motley Fool
More Likely to 5X First: CRISPR Therapeutics vs. InMode
January 12, 2023
These two companies are in very different situations but could generate significant returns for investors.
Via
The Motley Fool
2 Growth Stocks You May Regret not Buying Right Now
January 11, 2023
At their beaten-down valuations, these stocks have the potential to deliver some impressive returns.
Via
The Motley Fool
Can Cathie Wood Bounce Back in 2023?
January 11, 2023
Wood sticks by her strategy, no matter what the general market does.
Via
The Motley Fool
2 Supercharged Stocks to Buy Right Now That Could Soar in 2023
January 11, 2023
These stocks have been solid performers despite the macroeconomic uncertainties in 2022.
Via
The Motley Fool
2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years
January 07, 2023
Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow.
Via
The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2023
January 06, 2023
These biotechnology stocks are pushing ahead with promising innovations.
Via
The Motley Fool
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
January 06, 2023
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.
Via
Investor's Business Daily
Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away'
January 04, 2023
Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams.
Via
Benzinga
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Rich Over Time
January 04, 2023
Wood is bargain hunting now. And these buys may pay off big in the long run.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.